Since DNA damage checkpoint kinases ATR and WEE1 are among key regulators of DNA damage/repair pathways26, we then estimated the IC50 for WEE1 (AZD1775) and ATR (AZD6738) inhibitors based on promising early clinical trial results in other cancer types27–31. This evidence concerns the gene WEE1 and cancer.